Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Medrol [legacy through FY23] by Year
Medrol (methylprednisolone) [legacy through FY23] — Worldwide reported YoY (%) (%)
Pfizer Medrol [legacy through FY23]: 9.0% in FY2023, up 16.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
“|| Medrol | 61 | 56 | 9% | 7% | 39 | 36 | 8% | 14% | 106 | 103 | 3% | 5%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Medrol (methylprednisolone) [legacy through FY23] — Worldwide reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 9.0% | +16.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2022 | Dec 31, 2022 | -7.0% | -17.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | 10.0% | +28.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗ |
| FY2020 | Dec 31, 2020 | -18.0% | -9.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗ |
| FY2019 | Dec 31, 2019 | -9.0% | +3.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312019xex99.htm, filed 2020-01-28) ↗ |
| FY2018 | Dec 31, 2018 | -12.0% | -19.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312018xex99.htm, filed 2019-01-29) ↗ |
| FY2017 | Dec 31, 2017 | 7.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312017xex99.htm, filed 2018-01-30) ↗ |
Cite this data
StockData. (2026). Pfizer Medrol [legacy through FY23] (%), annual FY2017–FY2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/medrol-leg-yoy-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.